Skip to main content
SpringerLink
Log in

DAPT-Studie

Der Nutzen einer verlängerten dualen Plättchenhemmung überwiegt die blutungsassoziierten Nachteile bei Patienten nach Implantation beschichteter Koronarstents

DAPT study

Benefit of prolonged dual antipletelet therapy outweighs bleeding-associated disadvantages in patients after implantation of drug-eluting stents

  • Journal Club
  • Published:
Der Kardiologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Authors/Task Force members, Windecker S, Kolh P et al (2014) 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35:2541–2619

    Article  Google Scholar 

  2. Levine GN, Bates ER, Blankenship JC et al (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58:e44–e122

    Article  PubMed  Google Scholar 

  3. Collet JP, Silvain J, Barthelemy O et al (2014) Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet 384:1577–1585

    Article  CAS  PubMed  Google Scholar 

  4. Mauri L, Kereiakes DJ, Yeh RW et al (2014) Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371:2155–2166

    Article  CAS  PubMed  Google Scholar 

  5. Feres F, Costa RA, Abizaid A et al (2013) Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 310:2510–2522

    CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt

C. Özcelik gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinikum VEST, Knappschaftskrankenhaus Recklinghausen, Dorstener Str. 151, 45657, Recklinghausen, Deutschland

    C. Özcelik

Authors
  1. C. Özcelik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Özcelik.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Özcelik, C. DAPT-Studie. Kardiologe 9, 7–8 (2015). https://doi.org/10.1007/s12181-014-0643-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12181-014-0643-3

Search

Navigation